| Multiplexed lipid dip‐pen nanolithography on subcellular scales for the templating of functional proteins and cell culture S Sekula, J Fuchs, S Weg‐Remers, P Nagel, S Schuppler, J Fragala, ... small 4 (10), 1785-1793, 2008 | 204 | 2008 |
| Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays A Carlsson, C Wingren, J Ingvarsson, P Ellmark, B Baldertorp, M Fernö, ... European journal of cancer 44 (3), 472-480, 2008 | 175 | 2008 |
| Detection of pancreatic cancer using antibody microarray‐based serum protein profiling J Ingvarsson, C Wingren, A Carlsson, P Ellmark, B Wahren, G Engström, ... Proteomics 8 (11), 2211-2219, 2008 | 172 | 2008 |
| Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays P Ellmark, J Ingvarsson, A Carlsson, BS Lundin, C Wingren, ... Molecular & Cellular Proteomics 5 (9), 1638-1646, 2006 | 143 | 2006 |
| The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation AM Kvarnhammar, N Veitonmäki, K Hägerbrand, A Dahlman, KE Smith, ... Journal for immunotherapy of cancer 7 (1), 103, 2019 | 125 | 2019 |
| The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell–dependent tumor immunity SM Mangsbo, S Broos, E Fletcher, N Veitonmäki, C Furebring, E Dahlén, ... Clinical Cancer Research 21 (5), 1115-1126, 2015 | 125 | 2015 |
| Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer LC Sandin, A Orlova, E Gustafsson, P Ellmark, V Tolmachev, ... Cancer immunology research 2 (1), 80-90, 2014 | 120* | 2014 |
| First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies SMM Irenaeus, D Nielsen, P Ellmark, J Yachnin, A Deronic, A Nilsson, ... International journal of cancer 145 (5), 1189-1199, 2019 | 110 | 2019 |
| Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo LC Sandin, F Eriksson, P Ellmark, ASI Loskog, TH Tötterman, ... Oncoimmunology 3 (1), e27614, 2014 | 101 | 2014 |
| Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer L van Hooren, LC Sandin, I Moskalev, P Ellmark, A Dimberg, P Black, ... European journal of immunology 47 (2), 385-393, 2017 | 90 | 2017 |
| Multiplex detection of surface molecules on colorectal cancers P Ellmark, L Belov, P Huang, CS Lee, MJ Solomon, DK Morgan, ... Proteomics 6 (6), 1791-1802, 2006 | 87 | 2006 |
| CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation I Otano, A Azpilikueta, J Glez-Vaz, M Alvarez, J Medina-Echeverz, ... Nature communications 12 (1), 7296, 2021 | 79 | 2021 |
| Affinity and Epitope Profiling of Mouse Anti‐CD40 Monoclonal Antibodies ACM Hager, P Ellmark, CAK Borrebaeck, C Furebring Scandinavian journal of immunology 57 (6), 517-524, 2003 | 58 | 2003 |
| Modulation of the CD40–CD40 ligand interaction using human anti‐CD40 single‐chain antibody fragments obtained from the n‐CoDeR phage display library P Ellmark, C Ottosson, CAK Borrebaeck, AC Malmborg Hager, ... Immunology 106 (4), 456-463, 2002 | 44 | 2002 |
| Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy M Georganaki, M Ramachandran, S Tuit, NG Núñez, A Karampatzakis, ... Oncoimmunology 9 (1), 1730538, 2020 | 43 | 2020 |
| Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression JPO Hebb, AR Mosley, F Vences-Catalán, N Rajasekaran, A Rosén, ... Cancer Immunology, Immunotherapy 67 (1), 47-60, 2018 | 43 | 2018 |
| Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation P Ellmark, SM Mangsbo, C Furebring, P Norlén, TH Tötterman Cancer Immunology, Immunotherapy 66 (1), 1-7, 2017 | 43 | 2017 |
| Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study JL Van Laethem, I Borbath, H Prenen, KP Geboes, A Lambert, E Mitry, ... The Lancet Oncology 25 (7), 853-864, 2024 | 39 | 2024 |
| Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy K Enell Smith, A Deronic, K Hägerbrand, P Norlén, P Ellmark Expert opinion on biological therapy 21 (12), 1635-1646, 2021 | 38 | 2021 |
| CD86 variants with improved affinity for CTLA-4 P Ellmark, C Furebring, E Dahlen US Patent 9,834,589, 2017 | 33 | 2017 |
